Cognition Therapeutics, Inc.

Check out the recent coverage in Alzheimer's News Today - CT1812 slows cognitive decline in proof-of-concept clinical trial #AlzheimersDisease #ClinicalTrials #CognitiveDecline https://lnkd.in/g2dmT5y9

Read our announcement from this morning - Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease -#Alzheimers #EEG #ClinicalTrials - https://lnkd.in/eCkf_EMz

Results from the SEQUEL study were published in The Journal of Prevention of Alzheimer's Disease (JPAD). If you recall, SEQUEL measured brain wave patterns in 16 adults with mild-to-moderate #Alzheimers disease following 29-days of oral QD CT1812 or placebo. Consistent trends of improvement were observed across EEG parameters indicating that CT1812 may normalize synaptic function. The article is available online: https://lnkd.in/dAufNWYi

Check out the latest from NeuroVoices: Anthony Caggiano, MD, PhD, on Therapeutic Progress of Alzheimer Agent CT1812 - from Marco Meglio & NeurologyLive #Alzheimers #clinicaltrial https://lnkd.in/gTsEqWnQ

From our 2nd Quarter update last week. See the full release and listen to the full recording here #AlzheimersDisease #clinicaltrials #dementia https://lnkd.in/eQq9YdJF

As a reminder, we are hosting a conference call and webcast today, August 8, 2024 at 8:30am ET / 5:30am PT to review our 2nd quarter financial results. Visit our website for the latest press release and dial-in instructions.

More from last week's coverage of the news on our Proof-of-Concept Phase 2 SHINE Trial - check it out at Genetic Engineering & Biotechnology News #Alzheimersdisease https://lnkd.in/e6erQ537

Marco Meglio, thanks for taking the time to speak with us at #AAIC24 about our Phase 2 proof-of-concept SHINE #clinicaltrial results in mild-to-moderate #Alzheimers disease. We look forward to keeping you apprised of our progress.

More from CEO Lisa Ricciardi in today's announcement - “We believe these results provide evidence that amyloid oligomer antagonism – a new and distinct mechanism for therapeutic intervention – may have a role as a monotherapy or in a combination with approved drugs for the treatment of AD and related dementias. In terms of percent improvement on evaluated cognitive measures, our results are comparable in magnitude to what was achieved with currently approved antibodies, with great ease of administration as a once daily dose, and less patient burden.” #Alzheimer's #AAIC24 #patientburden https://lnkd.in/eRrg5aQQ

Check out our announcement this morning - Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients #alzheimers #AAIC24 https://lnkd.in/eRrg5aQQ